摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(±)-2-phenyl-1,4-benzoxazin-3-one-8-carboxylic acid | 579525-27-2

中文名称
——
中文别名
——
英文名称
(±)-2-phenyl-1,4-benzoxazin-3-one-8-carboxylic acid
英文别名
(+/-)-2-phenyl-1,4-benzoxazin-3-one-8-carboxylic acid;3-oxo-2-phenyl-3,4-dihydro-2H-1,4-benzoxazine-8-carboxylicacid;3-oxo-2-phenyl-4H-1,4-benzoxazine-8-carboxylic acid
(±)-2-phenyl-1,4-benzoxazin-3-one-8-carboxylic acid化学式
CAS
579525-27-2
化学式
C15H11NO4
mdl
——
分子量
269.257
InChiKey
ZMZYMWQUNWEEHF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    536.1±50.0 °C(Predicted)
  • 密度:
    1.369±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    75.6
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (±)-2-phenyl-1,4-benzoxazin-3-one-8-carboxylic acid甲醇 、 sodium tetrahydroborate 、 三氟化硼乙醚 、 sodium carbonate 作用下, 以 四氢呋喃乙醚 为溶剂, 反应 2.58h, 生成 (±)-4-trifluoroacetyl-2-phenyl-1,4-benzoxazine-8-methanol
    参考文献:
    名称:
    ANTI-MALIGNANT TUMOR AGENT COMPOSITION
    摘要:
    公开号:
    EP2959918B1
  • 作为产物:
    描述:
    3-硝基水杨酸硫酸铁粉potassium carbonate溶剂黄146 、 lithium hydroxide 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 34.0h, 生成 (±)-2-phenyl-1,4-benzoxazin-3-one-8-carboxylic acid
    参考文献:
    名称:
    2,3-二氢苯并[b][1,4]二恶英-5-甲酰胺和3-氧代-3,4-二氢苯并[b][1,4]恶嗪-8-甲酰胺衍生物作为PARP1抑制剂的合成。
    摘要:
    聚(ADP-核糖)聚合酶 1 (PARP1) 是一种广泛探索的抗癌药物靶点,在单链 DNA 断裂修复过程中发挥着重要作用。使用 PARP1-苯并咪唑-4-甲酰胺晶体结构和药效团模型对 Maybridge 小分子文库进行高通量虚拟筛选 (HTVS),鉴定出 11 种化合物。使用重组 PARP1 酶测定法评估这些化合物,从而获得三种 PARP1 抑制剂:3 (IC 50 = 12 μM)、4 (IC 50 = 5.8 μM) 和10 (IC 50 = 0.88 μM)。化合物4(2,3-dihydro-1,4-benzodioxine-5-carboxamide) 被选为先导化合物,并对其进行了进一步的化学修饰,包括类似物合成和支架跳跃。这些努力导致了 ( Z )-2-(4-hydroxybenzylidene)-3-oxo-3,4-dihydro-2 H - benzo[ b ][1,4]o
    DOI:
    10.1016/j.bioorg.2020.104075
点击查看最新优质反应信息

文献信息

  • Aromatic amino acid derivates and medicinal compositions
    申请人:Endo Hitoshi
    公开号:US20050119256A1
    公开(公告)日:2005-06-02
    1. An aromatic amino acid derivative represented by the formula (I) or its pharmacologically acceptable salt: wherein, R 1 is a hydrogen atom or an amino-protecting group, R 2 is a halogen atom or an alkyl, aralkyl or aryl group, R 3 is circle over (1)} a hydrogen atom, circle over (2)} an aroylamino group, circle over (3)} a phenyl group substituted with lower alkyl, phenyl, phenoxy, etc. circle over (4)} a naphthyl or tetrahydronaphthyl group optionally substituted with hydroxy, lower alkoxy or di(lower)alkylamino, circle over (5)} an unsaturated mono-cyclic heterocyclic group containing N, O and/or S substituted with lower alkyl, phenyl, naphthyl or tetrahydroquinolyl, circle over (6)} an unsaturated or partially saturated condensed heterocyclic group containing N, O and/or S, optionally substituted with oxo, carboxy, amino, lower alkyl, etc.; X is a halogen atom, an alkyl group or an alkoxy group; Y is oxygen atom or nitrogen atom; I is 0 or 1; m is 0, 1 or 2; n is an integer of 0-5. This compound can inhibit a transporter (LAT1) of essential amino acid which is one of main nutrition for cancer cells and accordingly cause drain of the essential amino acid on the cancer cells and finally can prohibit the multiplication of cancer cells.
    一种芳香族氨基酸衍生物,其化学式为(I)或其药理学上可接受的盐:其中,R1为氢原子或氨基保护基;R2为卤素原子或烷基、芳基烷基或芳基基团;R3为circle over (1)}氢原子,circle over (2)}芳基氨基基团,circle over (3)}苯基,其取代基为较低的烷基、苯基、苯氧基等,circle over (4)}萘基或四氢萘基,可选地取代羟基、较低的烷氧基或二(较低)烷基氨基,circle over (5)}含N、O和/或S的不饱和单环杂环基团,取代基为较低的烷基、苯基、萘基或四氢喹啉基团,circle over (6)}含N、O和/或S的不饱和或部分饱和的紧缩杂环基团,可选地取代为氧代、羧基、氨基、较低的烷基等;X为卤素原子、烷基或烷氧基;Y为氧原子或氮原子;I为0或1;m为0、1或2;n为0-5的整数。该化合物可以抑制癌细胞的主要营养物质之一的必需氨基酸转运体(LAT1),从而导致癌细胞必需氨基酸的流失,最终可以抑制癌细胞的增殖。
  • Aromatic amino acid derivatives and medicinal compositions
    申请人:——
    公开号:US07345068B2
    公开(公告)日:2008-03-18
    1. An aromatic amino acid derivative represented by the formula (I) or its pharmacologically acceptable salt: wherein, R1 is a hydrogen atom or an amino-protecting group, R2 is a halogen atom or an alkyl, aralkyl or aryl group, R3 is circle around (1)} a hydrogen atom, circle around (2)} an aroylamino group, circle around (3)} a phenyl group substituted with lower alkyl, phenyl, phenoxy, etc. circle around (4)} a naphthyl or tetrahydronaphthyl group optionally substituted with hydroxy, lower alkoxy or di(lower)alkylamino, circle around (5)} an unsaturated mono-cyclic heterocyclic group containing N, O and/or S substituted with lower alkyl, phenyl, naphthyl or tetrahydroquinolyl, circle around (6)} an unsaturated or partially saturated condensed heterocyclic group containing N, O and/or S, optionally substituted with oxo, carboxy, amino, lower alkyl, etc.; X is a halogen atom, an alkyl group or an alkoxy group; Y is oxygen atom or nitrogen atom; l is 0 or 1; m is 0, 1 or 2; n is an integer of 0-5. This compound can inhibit a transporter (LAT1) of essential amino acid which is one of main nutrition for cancer cells and accordingly cause drain of the essential amino acid on the cancer cells and finally can prohibit the multiplication of cancer cells.
    一种芳香族氨基酸衍生物,其化学式为(I)或其药学上可接受的盐:其中,R1是氢原子或氨基保护基,R2是卤素原子或烷基、芳基烷基或芳基基团,R3是圆圈1}氢原子,圆圈2}芳酰氨基基团,圆圈3}苯基取代较低烷基、苯基、苯氧基等的基团,圆圈4}萘基或四氢萘基基团,可选地取代羟基、较低烷氧基或二(较低)烷基氨基,圆圈5}含有N、O和/或S的不饱和单环杂环基团,取代较低烷基、苯基、萘基或四氢喹啉基团,圆圈6}含有N、O和/或S的不饱和或部分饱和的紧缩杂环基团,可选地取代氧代、羧基、氨基、较低烷基等;X是卤素原子、烷基或烷氧基;Y是氧原子或氮原子;l为0或1;m为0、1或2;n为0-5的整数。该化合物可以抑制癌细胞的主要营养物质之一的必需氨基酸的转运体(LAT1),从而导致癌细胞中必需氨基酸的流失,最终可以抑制癌细胞的增殖。
  • AROMATIC AMINO ACID DERIVATIVES AND MEDICINAL COMPOSITIONS
    申请人:Endo, Hitoshi
    公开号:EP1481965B1
    公开(公告)日:2015-07-29
  • US7345068B2
    申请人:——
    公开号:US7345068B2
    公开(公告)日:2008-03-18
  • Synthesis of 2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide and 3-oxo-3,4-dihydrobenzo[b][1,4]oxazine-8-carboxamide derivatives as PARP1 inhibitors
    作者:Xuwei Shao、Steven Pak、Uday Kiran Velagapudi、Shruthi Gobbooru、Sai Shilpa Kommaraju、Woon-Kai Low、Gopal Subramaniam、Sanjai Kumar Pathak、Tanaji T. Talele
    DOI:10.1016/j.bioorg.2020.104075
    日期:2020.9
    using recombinant PARP1 enzyme assay that resulted in the acquisition of three PARP1 inhibitors: 3 (IC50 = 12 μM), 4 (IC50 = 5.8 μM), and 10 (IC50 = 0.88 μM). Compound 4 (2,3-dihydro-1,4-benzodioxine-5-carboxamide) was selected as a lead and it was subjected to further chemical modifications, involving analogue synthesis and scaffold hopping. These efforts led to the identification of (Z)-2-(4-hydroxy
    聚(ADP-核糖)聚合酶 1 (PARP1) 是一种广泛探索的抗癌药物靶点,在单链 DNA 断裂修复过程中发挥着重要作用。使用 PARP1-苯并咪唑-4-甲酰胺晶体结构和药效团模型对 Maybridge 小分子文库进行高通量虚拟筛选 (HTVS),鉴定出 11 种化合物。使用重组 PARP1 酶测定法评估这些化合物,从而获得三种 PARP1 抑制剂:3 (IC 50 = 12 μM)、4 (IC 50 = 5.8 μM) 和10 (IC 50 = 0.88 μM)。化合物4(2,3-dihydro-1,4-benzodioxine-5-carboxamide) 被选为先导化合物,并对其进行了进一步的化学修饰,包括类似物合成和支架跳跃。这些努力导致了 ( Z )-2-(4-hydroxybenzylidene)-3-oxo-3,4-dihydro-2 H - benzo[ b ][1,4]o
查看更多